Abstract
A novel series of 2-piperidinyl quinoline chalcones/amines (3-21) as structural analogues of quipazine were designed in order to find a promising candidate having antidepressant potential. They were synthesized, characterized and screened in vivo for their antidepressant potential by two behavioural models viz. forced swim test (FST) and learned helplessness test (LST). FST showed that compound 5, 8 and 17 reduced significantly the duration of immobility at 20 mg/kg, when compared with the control (p<0.001), and demonstrated comparable activity to clomipramine (p<0.001). LST further supported the antidepressant potential of these compounds. Furthermore, in 5-HTP-induced head-twitch test and yohimbine-induced mortality test, most active compound 5 increased the rate of head-twitching and the prevalence of mortality. Thus, the mechanism of action of the antidepressant effects of compound 1-(2,4-Dichlorophenyl)-3-[2- (piperidin-1-yl) quinolin-3-yl] prop-2-en-1-one (5) may be attributed to increased 5HT and NE level in the synapse.
Keywords: Antidepressant behavioral test, Chalcone, 5-HTP induced mouse head-twitch test, Molinspiration, 2-Piperidinyl quinoline, Quipazine, Reductive amination, Schiff’s base, Yohimbine toxicity potentiation test, catecholamines
Letters in Drug Design & Discovery
Title:Design, Synthesis and Evaluation of Novel 2-piperidinyl Quinoline Chalcones/ Amines as Potential Antidepressant Agents
Volume: 10 Issue: 1
Author(s): Obaid Afzal, Sandhya Bawa, Suresh Kumar, Rajiv Kumar and Md Quamrul Hassan
Affiliation:
Keywords: Antidepressant behavioral test, Chalcone, 5-HTP induced mouse head-twitch test, Molinspiration, 2-Piperidinyl quinoline, Quipazine, Reductive amination, Schiff’s base, Yohimbine toxicity potentiation test, catecholamines
Abstract: A novel series of 2-piperidinyl quinoline chalcones/amines (3-21) as structural analogues of quipazine were designed in order to find a promising candidate having antidepressant potential. They were synthesized, characterized and screened in vivo for their antidepressant potential by two behavioural models viz. forced swim test (FST) and learned helplessness test (LST). FST showed that compound 5, 8 and 17 reduced significantly the duration of immobility at 20 mg/kg, when compared with the control (p<0.001), and demonstrated comparable activity to clomipramine (p<0.001). LST further supported the antidepressant potential of these compounds. Furthermore, in 5-HTP-induced head-twitch test and yohimbine-induced mortality test, most active compound 5 increased the rate of head-twitching and the prevalence of mortality. Thus, the mechanism of action of the antidepressant effects of compound 1-(2,4-Dichlorophenyl)-3-[2- (piperidin-1-yl) quinolin-3-yl] prop-2-en-1-one (5) may be attributed to increased 5HT and NE level in the synapse.
Export Options
About this article
Cite this article as:
Afzal Obaid, Bawa Sandhya, Kumar Suresh, Kumar Rajiv and Quamrul Hassan Md, Design, Synthesis and Evaluation of Novel 2-piperidinyl Quinoline Chalcones/ Amines as Potential Antidepressant Agents, Letters in Drug Design & Discovery 2013; 10 (1) . https://dx.doi.org/10.2174/1570180811309010075
DOI https://dx.doi.org/10.2174/1570180811309010075 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Tumor Targeting with RGD Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers
Anti-Cancer Agents in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Microwave-Assisted Domino Cyclization Reactions
Current Microwave Chemistry Astatine-211: Production and Availability
Current Radiopharmaceuticals Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry The TCR/CD3 Complex: Opening the Gate to Successful Vaccination
Current Pharmaceutical Design Inhibitory Activity of Curcumin Derivatives Towards Metal-Free and Metal-Induced Amyloid-β Aggregation
Current Alzheimer Research Molecular Biology of the Enzymes that Degrade Endocannabinoids
Current Drug Targets - CNS & Neurological Disorders Sirtuins: Common Targets in Aging and in Neurodegeneration
Current Drug Targets Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research